BioSpectrum the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

SRL Diagnostics launches Fatty Liver Index

12 July 2022 | News

First line diagnostic test for Non Alcoholic Fatty Liver Diseases



SRL Diagnostics has launched of 'Fatty Liver Index', a first-line diagnostic test for non-alcoholic fatty liver disease.

Fatty Liver Index (FLI) is an algorithm-based index that includes multiple parameters; results of the GGT test (gamma-glutamyl-transferase), triglycerides test (TG), weight, height, body mass index (BMI) and waist circumference for the prediction of non-alcoholic fatty liver disease (NAFLD).

Anand. K, Chief Executive Officer, SRL Diagnostics said, “Epidemiological studies suggest prevalence of NAFLD is around 9% to 32% of general population in India with higher prevalence in those who are overweight or obese and those with diabetes or pre-diabetes. Additionally NAFLD has also emerged as one of the leading causes of cirrhosis, hepatocellular carcinoma and liver transplant in India. India is the first country to have added NAFLD to one of its national disease control programs by integrating it into the *National Program on Prevention and Control of Cancer, Diabetes, Cardiovascular disease and Stroke* by the Ministry of Health and Family Welfare. Precise diagnosis is the first step in disease control and we are proud to lead this initiative for NAFLD.”